Editors' ChoiceAlzheimer’s Disease

GALvanizing Alzheimer’s disease therapy to combat the inflamed brain

See allHide authors and affiliations

Science Translational Medicine  08 May 2019:
Vol. 11, Issue 491, eaax8310
DOI: 10.1126/scitranslmed.aax8310


Galectin-3 is elevated in patients with Alzheimer’s disease (AD), and its deletion reduces neuroinflammation and β-amyloid burden in a mouse model of AD.

View Full Text

Stay Connected to Science Translational Medicine